CHINA NATIONAL PHARMACEUTICAL GROUP
China National Pharmaceutical Group, commonly known as Sinopharm, is a leading player in the pharmaceutical and healthcare industry, headquartered in Beijing, China. Established in 1998, Sinopharm has rapidly expanded its operations across various regions, including Asia, Europe, and Africa, solidifying its position as a global healthcare provider. The company focuses on the research, development, manufacturing, and distribution of pharmaceuticals, medical devices, and healthcare services. Sinopharm is particularly renowned for its extensive portfolio of vaccines and innovative biopharmaceuticals, which are distinguished by their quality and efficacy. With a strong market presence, Sinopharm has achieved significant milestones, including being listed among the Fortune Global 500. Its commitment to advancing healthcare solutions continues to drive its reputation as a trusted leader in the pharmaceutical sector.
DitchCarbon Score
How does CHINA NATIONAL PHARMACEUTICAL GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CHINA NATIONAL PHARMACEUTICAL GROUP's score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CHINA NATIONAL PHARMACEUTICAL GROUP's reported carbon emissions
In 2023, China National Pharmaceutical Group (Sinopharm) reported total carbon emissions of approximately 26,341,5270 kg CO2e, comprising about 54,715,050 kg CO2e from Scope 1 and about 208,700,220 kg CO2e from Scope 2 emissions. This marks a slight increase from 2022, where total emissions were about 25,310,5280 kg CO2e, with Scope 1 emissions at approximately 52,434,340 kg CO2e and Scope 2 emissions at about 200,670,940 kg CO2e. Sinopharm has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. The company has not set specific reduction targets or initiatives, as evidenced by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). Overall, while Sinopharm has made strides in tracking its emissions, the lack of reduction commitments suggests an opportunity for enhanced climate action and transparency in its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 30,741,540 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 88,611,470 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CHINA NATIONAL PHARMACEUTICAL GROUP is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
